The US Food and Drug Administration (FDA) has approved sacubitril/valsartan (Entresto, Novartis) for the treatment of symptomatic heart failure (HF) with systemic left ventricular systolic dysfunction ...

In patients with severe left ventricular systolic dysfunction on optimal medical therapy for HF, undergoing PCI did not improve rates of all-cause death or HF hospitalization, according to the results ...

Cardiomyopathy is the leading cause of mortality in patients with DMD. Compared with their healthy counterparts, patients with DMD — including those with preserved left ventricular ejection fraction ...

An artificial intelligence (AI) algorithm trained to interpret single-lead ECGs from the Apple Watch accurately detected signs of subclinical left ventricular systolic dysfunction in a ...

Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic ...

Cardiac arrhythmias following myocardial infarction (MI) predict poor outcome. β-blockers are effective ventricular antiarrhythmics and angiotensin-converting-enzyme (ACE) inhibitors can prevent both ...